You are here

Keytruda

5 takeaways from the first look at cancer's biggest conference

5 takeaways from the first look at cancer's biggest conference

Biopharma Dive

Bristol-Myers Squibb

Jounce Therapeutics

Flag link:

Merck's Keytruda boosts response in hard-to-treat lung cancer

Merck's Keytruda boosts response in hard-to-treat lung cancer

Reuters

squamous cell lung cancer

Flag link:

Neon Therapeutics Treats First Patient in Ph Ib Trial Evaluating Personal Cancer Vaccine NEO-PV-01 Plus Keytruda/Chemo Combination

Neon Therapeutics Treats First Patient in Ph Ib Trial Evaluating Personal Cancer Vaccine NEO-PV-01 Plus Keytruda/Chemo Combination

CP Wire

Neon Therapeutics

personalized medicine

Flag link:

OncoSec to combine ImmunoPulse device with Merck’s immunotherapy in breast cancer trial

OncoSec to combine ImmunoPulse device with Merck’s immunotherapy in breast cancer trial

Drug Delivery Business News

OncoSec Medical

ImmunoPulse IL-12

triple negative breast cancer

Flag link:

Merck Teams With Moderna To Take On One Of The Toughest Targets In Cancer

Merck Teams With Moderna To Take On One Of The Toughest Targets In Cancer

Forbes

cancer vaccines

Flag link:

A tale of two lung cancer immunotherapies: Merck's Keytruda takes the reins

A tale of two lung cancer immunotherapies: Merck's Keytruda takes the reins

Medical Marketing and Media

Bristol-Myers Squibb

Flag link:

Incyte wipes out late-phase epacadostat program after pivotal failure of Keytruda combination

Incyte wipes out late-phase epacadostat program after pivotal failure of Keytruda combination

Fierce Biotech

Flag link:

Merck has submitted Keytruda combination for FDA approval

Merck has submitted Keytruda combination for FDA approval

Marketwatch

Flag link:

Merck, Bristol-Myers cancer drugs both beat expectations, but Merck beats them a little more

Merck, Bristol-Myers cancer drugs both beat expectations, but Merck beats them a little more

CNBC

Bristol-Myers Squibb

non-small cell lung cancer

Flag link:

Keytruda Adjuvant Therapy Study Shows Reduced the Risk of Disease Recurrence or Death by More Than 40 Percent Compared to Placebo in Stage III Melanoma

Keytruda Adjuvant Therapy Study Shows Reduced the Risk of Disease Recurrence or Death by More Than 40 Percent Compared to Placebo in Stage III Melanoma

CP Wire

anti-PD-1 immunotherapy

Flag link:

Keytruda Adjuvant Therapy Study Shows Reduced the Risk of Disease Recurrence or Death by More Than 40 Percent Compared to Placebo in Stage III Melanoma

Flag link:

With big Keytruda and Opdivo data coming at AACR, analyst hands Merck the early edge

With big Keytruda and Opdivo data coming at AACR, analyst hands Merck the early edge

Fierce Pharma

Bristol-Myers Squibb

Flag link:

Merck's stock surges after positive Keytruda trial results

Merck's stock surges after positive Keytruda trial results

Marketwatch

clinical trials

metastatic non-small cell lung cancer

Flag link:

Merck gets a lift, Pfizer a ding as analysts assess immuno-oncology, M&A outlook

Merck gets a lift, Pfizer a ding as analysts assess immuno-oncology, M&A outlook

Fierce Pharma

immuno-oncology

Flag link:

Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment

Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment

Marketwatch

clinical trials

metastatic melanoma

Flag link:

Preliminary positive results for Phase I - II trial of Tesaro's Zejula with Keytruda in platinum-resistant ovarian cancer (TSRO)

Preliminary positive results for Phase I - II trial of Tesaro's Zejula with Keytruda in platinum-resistant ovarian cancer (TSRO)

CP Wire

platinum-resistant ovarian cancer

clinical trials vaccines

Flag link:

Preliminary positive results for Phase I - II trial of Tesaro's Zejula with Keytruda in platinum-resistant ovarian cancer

platinum-resistant ovarian cancer

clinical trials

Flag link:

Roche's Tecentriq triumphs in squamous lung cancer. Can it make its mark against Merck?

Roche's Tecentriq triumphs in squamous lung cancer. Can it make its mark against Merck?

Fierce Pharma

squamous non-small cell lung cancer

Flag link:

Merck's Keytruda shows up its rivals with NICE backing in bladder cancer

Merck's Keytruda shows up its rivals with NICE backing in bladder cancer

Fierce Pharma

Flag link:

Incyte study could bring lessons for cancer immunotherapy

Incyte study could bring lessons for cancer immunotherapy

Biopharma Dive

cancer immunotherapy

metastatic melanoma

Flag link:

Pages